Journal
METABOLITES
Volume 7, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/metabo7020029
Keywords
isocitrate dehydrogenase; glioma; glioblastoma; 2-hydroxyglutarate; magnetic resonance spectroscopy
Categories
Funding
- NorthWest Cancer Research Centre, Liverpool, UK
Ask authors/readers for more resources
Mutations in the isocitrate dehydrogenase (IDH) 1/2 genes are highly prevalent in gliomas and have been suggested to play an important role in the development and progression of the disease. Tumours harbouring these mutations exhibit a significant alteration in their metabolism resulting in the aberrant accumulation of the oncometabolite 2-hydroxygluarate (2-HG). As well as being suggested to play an important role in tumour progression, 2-HG may serve as a surrogate indicator of IDH status through non-invasive detection using magnetic resonance spectroscopy (MRS). In this review, we describe the recent efforts in developing MRS methods for detection and quantification of 2-HG in vivo and provide an assessment of the role of the 2-HG in gliomagenesis and patient prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available